

Desmopressin acetate

200 microgram tablets;
10microgram/mL WCHN prepared solution;
4microgram/mL injection solution

© Department for Health and Ageing, Government of South Australia. All rights reserved.

Note:

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms

DDAVP

Dose and Indications

Treatment of Pituitary Diabetes Insipidus

Intranasal

Initially 0.25 micrograms per dose

Dose to be adjusted according to the response

Oral

Initially use 2 to 5 micrograms per dose, 1 to 3 times a day

Dose to be adjusted according to the response

Reported dosage equivalence for nasal to oral is 1:(10 - 20)

Haemostasis

Seek haematologist advice



Desmopressin acetate

200 microgram tablets; 10microgram/mL WCHN prepared solution;
4microgram/mL injection solution

Preparation and Administration

Intranasal

Preparation 1 (if WCHN prepared solution is unavailable):

Dilute 1mL of desmopressin 4microgram/mL injection solution with 3mL of 0.9% sodium chloride injection solution. The resulting solution contains 1microgram/mL of desmopressin acetate.

Administer using a syringe and alternate between each nostril until complete dose is given.

For 1microgram/mL solution:

Dose	0.25 microgram	0.5 microgram	1 microgram
Volume	0.25mL	0.5mL	1mL

The solution must be used immediately and the remainder discarded.

Preparation 2:


Use the solution prepared by the WCH Pharmacy department. This solution contains 10 micrograms/mL of desmopressin acetate.

For 10 microgram/mL solution:

Dose	0.25 microgram	0.5 microgram	1 microgram	1.5 microgram
Volume	0.025mL	0.05mL	0.1mL	0.15mL

Equipment required:

- 1 Rhinyle tube (*Rhinyle tubes are available from pharmacy and are reusable for individual patients*)



- 1 mL oral dispenser
- Straw attachment for the oral dispenser

Method for drawing up dose

1. Ensure you have the correct dilution of desmopressin acetate (10 micrograms/mL prepared by WCHN pharmacy).
2. Attach the straw attachment to 1mL oral dispenser.
3. Push straw attachment into the rhinyle tube at the END FURTHEST FROM THE ARROW.
4. Draw back on the dispenser until the fluid fills the rhinyle tube to the prescribed mark.
5. Hold rhinyle tube bent in a U shape with both openings facing upwards to avoid fluid loss.
6. Disconnect oral dispenser, leaving the straw attachment connected to the rhinyle tube.

Administration – Ensure the nose is clear and maintain rhinyle tube bent in U shape.

1. Draw 1mL of air into the oral dispenser.
2. Reconnect the oral dispenser to the straw attachment on the rhinyle tube at the END FURTHEST FROM THE ARROW.
3. Insert the rhinyle tube just inside the nostril.
4. Depress the oral dispenser quickly.

Desmopressin acetate

200 microgram tablets; 10microgram/mL WCHN prepared solution;
4microgram/mL injection solution

Oral

Place 100 micrograms (half a 200 microgram tablet) in a 10mL oral dispenser and draw up water to obtain a 10mL solution. The resulting solution contains 10 microgram/mL of desmopressin acetate.

Dose	2 microgram	3 microgram	4 microgram	5 microgram
Volume	0.2mL	0.3mL	0.4mL	0.5mL

The solution must be used immediately and the remainder discarded.

Adverse Effects

Common

Headache, abdominal cramps

Intranasal: local irritation and rhinitis in the nose, nosebleed

Infrequent

Water intoxication, seizures, hyponatraemia

Monitoring

- > Sodium levels
- > Fluid balance (Intake and urine output)

Practice Points

- > Always write the generic name of the drug in full and dose in micrograms.

References

Ooi H, Maguire A & Ambler G, Desmopressin administration in children with central diabetes insipidus: a retrospective review, J Pediatric Endocr Met, 2013; 26 (11-12); 1047-52



Desmopressin acetate

200 microgram tablets; 10microgram/mL WCHN prepared solution;
4microgram/mL injection solution

Document Ownership & History

Developed by:	SA Maternal, Neonatal & Gynaecology Community of Practice
Contact:	Health.NeoMed@sa.gov.au
Endorsed by:	SA Health Safety and Quality Strategic Governance Committee
Next review due:	15 November 2023
ISBN number:	978-1-76083-030-4
PDS reference:	CG197
Policy history:	Is this a new policy (V1)? N Does this policy amend or update an existing policy? Y If so, which version? V1.1 Does this policy replace another policy with a different title? N If so, which policy (title)?

Approval Date	Version	Who approved New/Revised Version	Reason for Change
15/11/2018	V2	SA Health Safety and Quality Strategic Governance Committee	Formally reviewed in line with 5 year scheduled timeline for review.
9/03/2018	V 1.1	SA Health Safety and Quality Strategic Governance Committee	Review date extended to 5 years following risk assessment. New Template
25/2/2015	V1	SA Health Safety and Quality Strategic Governance Committee	Original SA Health Safety and Quality Strategic Governance Committee approved version

